|
1
|
Pavlidis N and Pentheroudakis G: Cancer of
unknown primary site. Lancet. 379:1428–1435. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hess KR, Abbruzzese MC, Lenzi R, Raber MN
and Abbruzzese JL: Classification and regression tree analysis of
1000 consecutive patients with unknown primary carcinoma. Clin
Cancer Res. 5:3403–3410. 1999.PubMed/NCBI
|
|
3
|
Spurgeon L, Mitchell C, Cook N and Conway
AM: Cancer of unknown primary: The hunt for its elusive
tissue-of-origin - is it time to call off the search? Br J Cancer.
133:733–742. 2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kramer A, Bochtler T, Pauli C, Baciarello
G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T,
et al: Cancer of unknown primary: ESMO clinical practice guideline
for diagnosis, treatment and follow-up. Ann Oncol. 34:228–246.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Olivier T, Fernandez E, Labidi-Galy I,
Dietrich PY, Rodriguez-Bravo V, Baciarello G, Fizazi K and
Patrikidou A: Redefining cancer of unknown primary: Is precision
medicine really shifting the paradigm? Cancer Treat Rev.
97(102204)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Palmeri S, Lorusso V, Palmeri L, Vaglica
M, Porta C, Nortilli R, Ferraú F, Comella G, Massidda B and Danova
M: Carcinomas of Unknown Primary Italian Study Group. Cisplatin and
gemcitabine with either vinorelbine or paclitaxel in the treatment
of carcinomas of unknown primary site: Results of an Italian
multicenter, randomized, phase II study. Cancer. 107:2898–2905.
2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Raghav K: Cancer of unknown primary site.
N Engl J Med. 392:2035–2047. 2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Briasoulis E, Kalofonos H, Bafaloukos D,
Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C,
Kosmidis P and Pavlidis N: Carboplatin plus paclitaxel in unknown
primary carcinoma: A phase II Hellenic cooperative oncology group
study. J Clin Oncol. 18:3101–3107. 2000.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Haratani K, Hayashi H, Takahama T,
Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita
Y, et al: Clinical and immune profiling for cancer of unknown
primary site. J Immunother Cancer. 7(251)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Abu Sabbah T, Theurer S, Baba HA, Lueong
S, Rashidi-Alavijeh J, Hilser T, Zaun Y, Metzenmacher M,
Pogorzelski M, Virchow I, et al: PD-L1 expression associates with
favorable survival of patients with cancer of unknown primary (CUP)
not treated with checkpoint inhibitors. Eur J Cancer.
210(114268)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tanizaki J, Yonemori K, Akiyoshi K, Minami
H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y,
et al: Open-label phase II study of the efficacy of nivolumab for
cancer of unknown primary. Ann Oncol. 33:216–226. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Raghav KP, Stephen B, Karp DD, Piha-Paul
SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF,
Overman M, et al: Efficacy of pembrolizumab in patients with
advanced cancer of unknown primary (CUP): A phase 2 non-randomized
clinical trial. J Immunother Cancer. 10(e004822)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Culine S, Kramar A, Saghatchian M, Bugat
R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A and Fizazi K:
French Study Group on Carcinomas of Unknown Primary. Development
and validation of a prognostic model to predict the length of
survival in patients with carcinomas of an unknown primary site. J
Clin Oncol. 20:4679–4683. 2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Seve P, Ray-Coquard I, Trillet-Lenoir V,
Sawyer M, Hanson J, Broussolle C, Negrier S, Dumontet C and Mackey
JR: Low serum albumin levels and liver metastasis are powerful
prognostic markers for survival in patients with carcinomas of
unknown primary site. Cancer. 107:2698–2705. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Parsons HM, Forte ML, Abdi HI, Brandt S,
Claussen AM, Wilt T, Klein M, Ester E, Landsteiner A, Shaukut A, et
al: Nutrition as prevention for improved cancer health outcomes: A
systematic literature review. JNCI Cancer Spectr.
7(pkad035)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kuroda D, Sawayama H, Kurashige J,
Iwatsuki M, Eto T, Tokunaga R, Kitano Y, Yamamura K, Ouchi M,
Nakamura K, et al: Controlling nutritional status (CONUT) score is
a prognostic marker for gastric cancer patients after curative
resection. Gastric Cancer. 21:204–212. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hacker UT, Hasenclever D, Baber R, Linder
N, Busse H, Obermannova R, Zdrazilova-Dubska L, Valik D and Lordick
F: Modified Glasgow prognostic score (mGPS) is correlated with
sarcopenia and dominates the prognostic role of baseline body
composition parameters in advanced gastric and esophagogastric
junction cancer patients undergoing first-line treatment from the
phase III EXPAND trial. Ann Oncol. 33:685–692. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang W, Tan Y, Li Y and Liu J: Neutrophil
to Lymphocyte ratio as a predictor for immune-related adverse
events in cancer patients treated with immune checkpoint
inhibitors: A systematic review and meta-analysis. Front Immunol.
14(1234142)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Watanabe H, Yamada T, Komori K, Hara K,
Kano K, Takahashi K, Kumazu Y, Fujikawa H, Numata M, Aoyama T, et
al: Effect of prognostic nutrition index in gastric or
gastro-oesophageal junction cancer patients undergoing nivolumab
monotherapy. In Vivo. 35:563–569. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ikuta Y, Takamori H, Sakamoto Y, Hashimoto
D, Chikamoto A, Kuroki H, Sakata K, Sakamoto K, Hayashi H, Imai K,
et al: The modified Glasgow Prognostic Score (mGPS) is a good
predictor of indication for palliative bypass surgery in patients
with unresectable pancreatic and biliary cancers. Int J Clin Oncol.
19:629–633. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Huebner G, Link H, Kohne CH, Stahl M,
Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE,
Schoffski P, et al: Paclitaxel and carboplatin vs gemcitabine and
vinorelbine in patients with adeno- or undifferentiated carcinoma
of unknown primary: A randomised prospective phase II trial. Br J
Cancer. 100:44–49. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang H, He F, Xu W and Cao Z: Clinical
features of cancer with unknown primary site (clinical features,
treatment, prognosis of cancer with unknown primary site). BMC
Cancer. 22(1372)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fusco MJ, Knepper TC, Balliu J, Del Cueto
A, Laborde JM, Hooda SM, Brohl AS, Bui MM and Hicks JK: Evaluation
of targeted next-generation sequencing for the management of
patients diagnosed with a cancer of unknown primary. Oncologist.
27:e9–e17. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hayashi H, Kurata T, Takiguchi Y, Arai M,
Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, et
al: Randomized phase II trial comparing site-specific treatment
based on gene expression profiling with carboplatin and paclitaxel
for patients with cancer of unknown primary site. J Clin Oncol.
37:570–579. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kang S, Jeong JH, Yoon S, Yoo C, Kim KP,
Cho H, Ryoo BY, Jung J and Kim JE: Real-world data analysis of
patients with cancer of unknown primary. Sci Rep.
11(23074)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Takamizawa S, Shimoi T, Yoshida M, Tokura
M, Yazaki S, Mizoguchi C, Saito A, Kita S, Yamamoto K, Kojima Y, et
al: Diagnostic value of tumor markers in identifying favorable or
unfavorable subsets in patients with cancer of unknown primary: A
retrospective study. BMC Cancer. 22(412)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al: Capecitabine and cisplatin with or without cetuximab for
patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dolan RD, McSorley ST, Horgan PG, Laird B
and McMillan DC: The role of the systemic inflammatory response in
predicting outcomes in patients with advanced inoperable cancer:
Systematic review and meta-analysis. Crit Rev Oncol Hematol.
116:134–146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Moran S, Martinez-Cardus A, Sayols S,
Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H,
Diaz-Lagares A, de Moura MC, et al: Epigenetic profiling to
classify cancer of unknown primary: A multicentre, retrospective
analysis. Lancet Oncol. 17:1386–1395. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hainsworth JD, Rubin MS, Spigel DR, Boccia
RV, Raby S, Quinn R and Greco FA: Molecular gene expression
profiling to predict the tissue of origin and direct site-specific
therapy in patients with carcinoma of unknown primary site: A
prospective trial of the Sarah Cannon research institute. J Clin
Oncol. 31:217–223. 2013.PubMed/NCBI View Article : Google Scholar
|
